175293-23-9|Ethonafide|2-(2'-(dimethylamino)ethyl)-1,2-dihydro-7-ethoxydibenz(de, h)isoquinoline-1,3-dione|-范德生物科技公司

Ethonafide

NMR下载 COA and HPLC MSDS下载
names：
2-(2'-(dimethylamino)ethyl)-1,2-dihydro-7-ethoxydibenz(de, h)isoquinoline-1,3-dione
CAS号：
175293-23-9
MDL Number：
MF(分子式)： C22H22N2O3 MW(分子量)： 362.42
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ethonafide
英文别名	AMP53
CAS号	175293-23-9
SMILES	O=C1N(CCN(C)C)C(C2=CC=CC3=C(OCC)C4=CC=CC=C4C1=C23)=O
Inchi	InChI=1S/C22H22N2O3/c1-4-27-20-15-9-6-5-8-14(15)19-18-16(20)10-7-11-17(18)21(25)24(22(19)26)13-12-23(2)3/h5-11H,4,12-13H2,1-3H3
InchiKey	CQZISUJEDPJJNF-UHFFFAOYSA-N
分子式 Formula	C22H22N2O3
分子量 Molecular Weight	362.42
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Ethonafide(CAS:175293-23-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Ethonafide is an anthracene-containing derivative of amonafide that belongs to the azonafide series of anticancer agents. The lack of cross-resistance in multidrug-resistant cancer cell lines and the absence of a quinone and hydroquinone moiety make ethonafide a potentially less cardiotoxic replacement for existing anthracene-containing anticancer agents. Ethonafide was cytotoxic against three human prostate cancer cell lines at nanomolar concentrations. Ethonafide was found to be better tolerated and more effective at inhibiting tumor growth compared with mitoxantrone in a human xenograft tumor regression mouse model. Mechanistically, we found that ethonafide inhibited topoisomerase II activity by stabilizing the enzyme-DNA complex, involving both topoisomerase IIalpha and -beta. In addition, ethonafide induced a potent G(2) cell cycle arrest in the DU 145 human prostate cancer cell line. By creating stable cell lines with decreased expression of topoisomerase IIalpha or -beta, we found that a decrease in topoisomerase IIalpha protein expression renders the cell line resistant to ethonafide. The decrease in sensitivity to ethonafide was associated with a decrease in DNA damage and an increase in DNA repair as measured by the neutral comet assay. These data demonstrate that ethonafide is a topoisomerase II poison and that it is topoisomerase IIalpha-specific in the DU 145 human prostate cancer cell line. (See http//www.ncbi.nlm.nih.gov/pubmed/17351106.)
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol. 2008 Feb 15;75(4):883-90. Epub 2007 Nov 4. PubMed PMID: 18062937; PubMed Central PMCID: PMC2271051.

[2]Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, Shi FD. Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. J Immunol. 2007 Dec 1;179(11):7415-23. PubMed PMID: 18025185.

[3] Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. J Pharmacol Exp Ther. 2007 Jun;321(3):1109-17. Epub 2007 Mar 9. PubMed PMID: 17351106.

[4] Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM, Alberts DS. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs. 2001 Mar;12(3):213-20. PubMed PMID: 11290869.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开